The “dawn phenomenon” (DP) describes a pattern in which episodes of hyperglycemia are experienced by patients with diabetes or prediabetes during the early morning hours (usually between 3:00 and 8:00 AM). It typically occurs in the absence of prior nocturnal hypoglycemia. The term was first coined by Schmidt and colleagues in 1981 to refer to a rise in morning...
Category: <span>Diabetes</span>
Post
Awakening to the Dawn Phenomenon in Diabetes
The “dawn phenomenon” (DP) describes a pattern in which episodes of hyperglycemia are experienced by patients with diabetes or prediabetes during the early morning hours (usually between 3:00 and 8:00 AM). It typically occurs in the absence of prior nocturnal hypoglycemia. Schmidt and colleagues first coined the term in 1981 to refer to a rise in morning...
Post
Detecting Type 2 Diabetes Through Voice: How Does It Work?
An international study, Colive Voice, presented at the European Association for the Study of Diabetes (EASD) 2024 conference, shows that patients with type 2 diabetes (T2D) have different voice characteristics compared with healthy controls of the same age and gender. These results “open up possibilities for developing a first-line, noninvasive, and rapid screening tool for T2D, feasible with just...
Post
Do certain diabetes drugs increase the risk of acute kidney injury in patients taking anti-cancer therapies?
by American Society of Nephrology Credit: Pixabay/CC0 Public Domain Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medications that are increasingly prescribed for patients with type 2 diabetes and congestive heart failure. Reports of GLP-1RA–associated acute kidney injury (AKI) have emerged, but the risk of GLP-1RA–associated AKI among patients on anti-cancer drugs is unclear. Surprisingly, new research suggests that...
Post
GLP-1 receptor agonist and SGLT2 inhibitor prescribing in people with type 1 diabetes
About The Study: Prescribing for both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors in a type 1 diabetes (T1D) population identified in a database increased between 2010 and 2023. Differences in characteristics of the overall T1D population and those newly prescribed the medications are often associated with elevated cardiorenal risk profiles, suggesting...
Post
People with type 2 diabetes who eat low-carb may be able to discontinue medication
Credit: CC0 Public Domain Adults with type 2 diabetes on a low-carbohydrate diet may see benefits to their beta-cell function, allowing them to better manage their disease and possibly discontinue medication, according to new research published in the Journal of Clinical Endocrinology & Metabolism. Beta-cells are endocrine cells in the pancreas that produce and release insulin, the hormone...
Post
New anti-obesity drug shows promise in preventing heart failure related to type 2 diabetes
Graphical abstract. Credit: Cell Reports (2024). DOI: 10.1016/j.celrep.2024.114573 A University of Alberta pharmacology researcher has discovered that a new experimental anti-obesity drug improves diastolic heart function in mice with type 2 diabetes independent of its weight loss effects, suggesting the drug may work as a treatment to prevent the most prevalent form of heart failure in people...
Post
Non-invasive ECG device for diabetics live-monitors your blood sugar
An ECG signal is used to predict blood sugar levels Singular Wings View 2 Images A new continuous glucose monitor (CGM) that is not only non-invasive but that predicts blood sugar levels from ECG data promises to shake up diabetes management. The device is being showcased at the 2024 Taiwan Innotech Expo. Continuous glucose monitors...
Post
Study finds tuberculosis changes liver metabolism and could promote diabetes
Scientists from the University of Leicester have discovered that tuberculosis disrupts glucose metabolism in the body University of Leicester Professor Andrea Cooper from the University of Leicester Credit: University of Leicester Scientists from the University of Leicester have discovered that tuberculosis disrupts glucose metabolism in the body. The findings, which have now been published in PLoS...
Post
A new injectable shows promise to prevent and treat hypoglycemia
October 2, 2024 by American Chemical Society Encapsulated glucagon for insulin-induced hypoglycemia dissolves when sugar levels get seriously low (less than 60 milligrams per deciliter, mg/dL), releasing the hormone into the bloodstream and triggering the liver to release glucose. At normal sugar levels (more than 100 mg/dL), the micelles remain intact, keeping glucagon inactive. Credit:...